EMA: Stimulating the development of medicines for children

EMA’s revision of class waiver list expected to push the exploration of many more medicines for use in children The European Medicines Agency’s Paediatric Committee (PDCO) has revised the current list of class waivers for medicines that are not required to submit a paediatric investigation plan (PIP). These are the most extensive revisions to date, and aim to better balance the need to support development of medicines in children with the goal of avoiding exposing children to unnecessary studies. The revisions will, hopefully, encourage companies to develop more new medicines for use in children.